Saturday 17 October 2026
Export IFRX’s income statement to Excel — free account
InflaRx N.V.
IFRX Healthcare Biotechnology
In the quarter to June 2026, revenue fell 128.9%, EPS grew 54.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.
1.32
0.12
−8.33%
Follow IFRX
InflaRx N.V. (IFRX) P/E ratio
InflaRx N.V. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| 5 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MGNX MacroGenics, Inc. compare | n/m |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| ALEC Alector, Inc. compare | n/m |
| IFRX InflaRx N.V. | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| CAMP CAMP4 Therapeutics Corporation compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| PLX Protalix BioTherapeutics, Inc. compare | 10.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)